Unit:
Κατεύθυνση Σακχαρώδης Διαβήτης και ΠαχυσαρκίαLibrary of the School of Health Sciences
Supervisors info:
Νικόλαος Τεντολούρης, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κωνσταντίνος Μακρυλάκης, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Αλέξανδρος Κόκκινος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Η χρήση της μετφορμίνης στην κύηση
Translated title:
Use of metformin in pregnancy
Summary:
Metformin is the cornerstone of treatment of diabetes mellitus. Although its administration during pregnancy has been thoroughly investigated over the past decades, its use remains controversial. Current evidence suggests that metformin is effective in achieving glycemic control in patients with GDM, while decreasing rates of weight gain during gestation, fetal macrosomia and neonatal hypoglycemia. Oral administration, low cost and good tolerance represent further advantages of metformin use during pregnancy. Insulin is the treatment of choice for pregnant women with pre-existing T2D; metformin can be used as a supplement for women requiring higher doses of insulin or those presenting with rapid weight gain. In pregnant women with PCOS, studies showed conflicting results. Specifically, the use of metformin was associated with a likely decreased rate of late miscarriage and preterm birth. However, it did not appear to positively affect pregnancy outcomes in obese non-diabetic pregnant women. Thus, metformin use is not currently recommended for non-diabetic pregnant women that are obese or suffer from PCOS. Even though short-term data indicate that metformin use is safe during pregnancy, the drug freely crosses the placenta and more data are required to assess its safety in the long term fetal outcomes.
Main subject category:
Health Sciences
Keywords:
Metformin, Pregnancy, Review, GDM, Offspring
Number of references:
124
